Insulin Given Before FDG Injection in a Diabetic Patient With a Pancreatic Mass
A 64-year-old woman with type 2 diabetes and a 3.2-cm pancreatic mass is referred for FDG PET/CT. She fasted for 6 hours, but her point-of-care blood glucose is 268 mg/dL. The technologist calls the endocrinologist, who orders 8 units of regular insulin subcutaneously. Forty minutes later, glucose is 142 mg/dL, and the technologist injects 370 MBq (10 mCi) of F-18 FDG. Imaging begins 60 minutes after injection. The PET images show diffuse intense uptake in skeletal muscle and myocardium, and the pancreatic mass has an SUVmax of 2.4, lower than the 5.8 seen on a prior scan. The patient is anxious and wants to complete the study today.
1. What is the likely cause of the muscle uptake and reduced tumor SUV? Explain the physiologic mechanism.
Read the worked answer
The insulin dose is the most likely cause. Insulin stimulates translocation of GLUT4 transporters to the plasma membrane of skeletal muscle and myocardium, increasing FDG uptake in those tissues. Because insulin was given 40 minutes before injection, its effect was near its peak during the FDG distribution and uptake phase. The intense, diffuse muscle and myocardial uptake is therefore an expected insulin effect, not tumor-specific uptake.
The tumor SUV is also likely falsely reduced. Hyperglycemia competes with FDG for GLUT-mediated transport, and insulin lowers plasma glucose while shifting FDG toward insulin-sensitive tissues. The combination reduces the fraction of injected FDG available to the pancreatic mass. The lower SUVmax of 2.4 compared with 5.8 on the prior study should not be interpreted as treatment response or as a reliable measure of tumor metabolism.
2. Should this scan be used to guide therapy? What would you recommend?
Read the worked answer
This scan should not be used as the basis for therapy decisions. The insulin-induced muscle uptake degrades image interpretation, and the tumor SUV is not comparable with the prior study. The study should be reported as limited or nondiagnostic for lesion characterization, with the reason documented.
The study should be rescheduled. Preparation should include a fast of at least 4–6 hours, a blood glucose check before injection, and a target glucose generally below about 200 mg/dL per institutional protocol. Short-acting insulin should not be given immediately before FDG injection; if insulin is clinically necessary, the scan should be delayed until the insulin effect has resolved and glucose is stable. The rescheduled scan should use the same uptake time and reconstruction as the prior study to allow comparison. If the patient cannot return, the images may be interpreted cautiously with clinical correlation, but the SUV should not be used quantitatively.